Overview

FX-322 in Sensorineural Hearing Loss

Status:
Completed

Trial end date:
2019-04-01

Target enrollment:

Participant gender:

Summary

This is a phase 1/2 single dose study of FX-322 compared to placebo in male and female adults otherwise healthy with stable sensorineural hearing loss.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Frequency Therapeutics